🇺🇸 FDA
Patent

US 11446357

Method for treating disease using FOXP3+CD4+ T cells

granted A61KA61K38/1709A61K38/177

Quick answer

US patent 11446357 (Method for treating disease using FOXP3+CD4+ T cells) held by Kyverna Therapeutics, Inc. expires Mon Sep 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Kyverna Therapeutics, Inc.
Grant date
Tue Sep 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K38/1709, A61K38/177, A61K38/1774, A61K38/1793